Testing a computer aid for Graves' disease treatment
Part of Eyes & vision, Hormones & metabolism, Immune system & allergy clinical trials.
This study compares computer-guided dosing of methimazole (a common thyroid medication) to standard care for people with active Graves' disease. It tests whether digital support helps manage treatment better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have active Graves' disease (confirmed by a recent blood test showing low TSH, high free T4, and positive TRAb antibodies within the last month)
- You must be 18 years or older
- You must either: not have started any thyroid medication yet, have been on it for less than 4 weeks, or have finished a previous course of treatment at least 4 weeks ago
- You cannot be pregnant
- You cannot have had radioactive iodine therapy before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests efgartigimod, a new medicine given by injection under the skin, to see if it can help control Graves' disease (an overactive thyroid condition). The goal is to reduce the need for other thyroid medications or help people stop taking them.
This study compares different treatment plans to see how well they control Graves’ disease and whether it comes back. It may help by identifying which approach works best to prevent relapse.
This trial tests an investigational drug called IMVT-1402 for people with Graves' disease whose thyroid is still overactive even while taking standard antithyroid medication. The goal is to see if the drug can better control thyroid hormone levels.
This trial tests a new drug called IMVT-1402 for adults with Graves' disease whose thyroid is still overactive despite taking antithyroid medication. The goal is to see if the drug can safely help control thyroid hormone levels.
This study tests whether efgartigimod, an injectable medication given under the skin, can help control overactive thyroid (Graves' disease) in adults already taking methimazole or carbimazole. The goal is to see if it reduces thyroid antibodies and improves thyroid hormone levels.
This study tests a new medication called MER511 for adults with Graves' disease. The goal is to see if it is safe and how it works when taken once or multiple times.
Hear when a new Graves Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.